PDK1 controls upstream PI3K expression and PIP 3 generation

Oncogene

Volumn 33, Issue 23, 2014, Pages 3043-3053

  Dieterle, A M ^a   Bohler P ^b   Keppeler, H ^a   Alers, S ^a   Berleth, N ^b   Driessen S ^b   Hieke, N ^b   Pietkiewicz, S ^b,f   Loffler A S ^b   Peter, C ^b   Gray, A ^c   Leslie, N R ^c,g   Shinohara, H ^d   Kurosaki, T ^d   Engelke, M ^e   Wienands, J ^e   Bonin, M ^a   Wesselborg, S ^b   Stork, B ^b  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

^d RIKEN Center for Integrative Medical Sciences   (Japan)

^e UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^f OTTO VON GUERICKE UNIVERSITY   (Germany)

^g HERIOT WATT UNIVERSITY   (United Kingdom)

Author keywords

Akt; B lymphocytes; PDK1; PI3K; survival

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; FORKHEAD TRANSCRIPTION FACTOR; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN KINASE B; RAPAMYCIN; TRANSCRIPTION FACTOR FOXO; TRANSCRIPTOME;

ANIMAL CELL; APOPTOSIS; ARTICLE; B LYMPHOCYTE; BINDING SITE; CELL MEMBRANE; CELL SURVIVAL; CONFOCAL MICROSCOPY; CONTROLLED STUDY; FEEDBACK SYSTEM; FLOW CYTOMETRY; GENE DELETION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MICROARRAY ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE; UPREGULATION;

MAMMALIA;

ANIMALS; CELL LINE; CELL MEMBRANE; CELL SURVIVAL; CHICKENS; FEEDBACK, PHYSIOLOGICAL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; JURKAT CELLS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHATIDYLINOSITOL PHOSPHATES; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84902197513     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.266     Document Type: Article

References (66)

1. Bunney TD, Katan M. Phosphoinositide signalling in cancer: beyond PI3K and PTEN. Nat Rev Cancer 2010; 10: 342-352.
2. Carnero A. The PKB/AKT pathway in cancer. Curr Pharm Des 2010; 16: 34-44.
3. Chalhoub N, Baker SJ. PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol 2009; 4: 127-150.
4. Cully M, You H, Levine AJ, Mak TW. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 2006; 6: 184-192. (Pubitemid 43292562)
5. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009; 9: 550-562.
6. Hers I, Vincent EE, Tavare JM. Akt signalling in health and disease. Cell Signal 2011; 23: 1515-1527.
7. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2: 489-501. (Pubitemid 37328931)
8. So L, Fruman DA. PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances. Biochem J 2012; 442: 465-481.
9. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006; 7: 606-619. (Pubitemid 44100518)
10. Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B. The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol 2010; 11: 329-341.
11. Liu Y, Bankaitis VA. Phosphoinositide phosphatases in cell biology and disease. Prog Lipid Res 2010; 49: 201-217.
12. Mora A, Komander D, van Aalten DM, Alessi DR. PDK1, the master regulator of AGC kinase signal transduction. Semin Cell Dev Biol 2004; 15: 161-170. (Pubitemid 38251644)
13. Pearce LR, Komander D, Alessi DR. The nuts and bolts of AGC protein kinases. Nat Rev Mol Cell Biol 2010; 11: 9-22.
14. Alessi DR, Deak M, Casamayor A, Caudwell FB, Morrice N, Norman DG et al. 3-Phosphoinositide-dependent protein kinase-1 (PDK1): structural and functional homology with the Drosophila DSTPK61 kinase. Curr Biol 1997; 7: 776-789. (Pubitemid 27441832)
15. Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PR, Reese CB et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol 1997; 7: 261-269. (Pubitemid 27176852)
16. Alessi DR, Kozlowski MT, Weng QP, Morrice N, Avruch J. 3-Phosphoinositidedependent protein kinase 1 (PDK1) phosphorylates and activates the p70 S6 kinase in vivo and in vitro. Curr Biol 1998; 8: 69-81. (Pubitemid 28104519)
17. Kobayashi T, Cohen P. Activation of serum- and glucocorticoid-regulated protein kinase by agonists that activate phosphatidylinositide 3-kinase is mediated by 3-phosphoinositide-dependent protein kinase-1 (PDK1) and PDK2. Biochem J 1999; 339: 319-328. (Pubitemid 29209961)
18. Kobayashi T, Deak M, Morrice N, Cohen P. Characterization of the structure and regulation of two novel isoforms of serum- and glucocorticoid-induced protein kinase. Biochem J 1999; 344: 189-197.
19. Dong LQ, Zhang RB, Langlais P, He H, Clark M, Zhu L et al. Primary structure, tissue distribution, and expression of mouse phosphoinositide- dependent protein kinase-1, a protein kinase that phosphorylates and activates protein kinase Czeta. J Biol Chem 1999; 274: 8117-8122.
20. Jensen CJ, Buch MB, Krag TO, Hemmings BA, Gammeltoft S, Frodin M. 90-kDa ribosomal S6 kinase is phosphorylated and activated by 3- phosphoinositidedependent protein kinase-1. J Biol Chem 1999; 274: 27168-27176.
21. Le Good JA, Ziegler WH, Parekh DB, Alessi DR, Cohen P, Parker PJ. Protein kinase C isotypes controlled by phosphoinositide 3-kinase through the protein kinase PDK1. Science 1998; 281: 2042-2045. (Pubitemid 28475494)
22. Park J, Leong ML, Buse P, Maiyar AC, Firestone GL, Hemmings BA. Serum and glucocorticoid-inducible kinase (SGK) is a target of the PI 3-kinase-stimulated signaling pathway. EMBO J 1999; 18: 3024-3033. (Pubitemid 29255611)
23. Pullen N, Dennis PB, Andjelkovic M, Dufner A, Kozma SC, Hemmings BA et al. Phosphorylation and activation of p70s6k by PDK1. Science 1998; 279: 707-710.
24. Bayascas JR. PDK1: the major transducer of PI 3-kinase actions. Curr Top Microbiol Immunol 2010; 346: 9-29.
25. Currie RA, Walker KS, Gray A, Deak M, Casamayor A, Downes CP et al. Role of phosphatidylinositol 3,4,5-Trisphosphate in regulating the activity and localization of 3-phosphoinositide-dependent protein kinase-1. Biochem J 1999; 337: 575-583.
26. Fayard E, Xue G, Parcellier A, Bozulic L, Hemmings BA. Protein kinase B (PKB/Akt), a key mediator of the PI3K signaling pathway. Curr Top Microbiol Immunol 2010; 346: 31-56.
27. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307: 1098-1101. (Pubitemid 40262113)
28. Burnett PE, Barrow RK, Cohen NA, Snyder SH, Sabatini DM. RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc Natl Acad Sci USA 1998; 95: 1432-1437. (Pubitemid 28103409)
29. Garcia-Martinez JM, Alessi DR. mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). Biochem J 2008; 416: 375-385.
30. Balendran A, Biondi RM, Cheung PC, Casamayor A, Deak M, Alessi DR. A 3-phosphoinositide-dependent protein kinase-1 (PDK1) docking site is required for the phosphorylation of protein kinase Czeta (PKCzeta) and PKC-related kinase 2 by PDK1. J Biol Chem 2000; 275: 20806-20813. (Pubitemid 30457673)
31. Biondi RM, Kieloch A, Currie RA, Deak M, Alessi DR. The PIF-binding pocket in PDK1 is essential for activation of S6K and SGK, but not PKB. EMBO J 2001; 20: 4380-4390. (Pubitemid 32772032)
32. Carracedo A, Pandolfi PP. The PTEN-PI3K pathway: of feedbacks and cross-Talks. Oncogene 2008; 27: 5527-5541.
33. Shinohara H, Maeda S, Watarai H, Kurosaki T. IkappaB kinase beta-induced phosphorylation of CARMA1 contributes to CARMA1 Bcl10 MALT1 complex formation in B cells. J Exp Med 2007; 204: 3285-3293.
34. Lawlor MA, Mora A, Ashby PR, Williams MR, Murray-Tait V, Malone L et al. Essential role of PDK1 in regulating cell size and development in mice. EMBO J 2002; 21: 3728-3738. (Pubitemid 34787046)
35. Takata M, Homma Y, Kurosaki T. Requirement of phospholipase C-gamma 2 activation in surface immunoglobulin M-induced B cell apoptosis. J Exp Med 1995; 182: 907-914.
36. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS et al. Akt promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor. Cell 1999; 96: 857-868. (Pubitemid 29165088)
37. Kops GJ, Medema RH, Glassford J, Essers MA, Dijkers PF, Coffer PJ et al. Control of cell cycle exit and entry by protein kinase B-regulated forkhead transcription factors. Mol Cell Biol 2002; 22: 2025-2036. (Pubitemid 34224611)
38. Kurosaki T. Regulation of BCR signaling. Mol Immunol 2011; 48: 1287-1291.
39. Feldman RI, Wu JM, Polokoff MA, Kochanny MJ, Dinter H, Zhu D et al. Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J Biol Chem 2005; 280: 19867-19874. (Pubitemid 41379514)
40. Los M, Maddika S, Erb B, Schulze-Osthoff K. Switching Akt: from survival signaling to deadly response. Bioessays 2009; 31: 492-495.
41. Nogueira V, Park Y, Chen CC, Xu PZ, Chen ML, Tonic I et al. Akt determines replicative senescence and oxidative or oncogenic premature senescence and sensitizes cells to oxidative apoptosis. Cancer Cell 2008; 14: 458-470.
42. Yamazoe M, Sonoda E, Hochegger H, Takeda S. Reverse genetic studies of the DNA damage response in the chicken B lymphocyte line DT40. DNA Repair (Amst) 2004; 3: 1175-1185. (Pubitemid 38997961)
43. Nagashima T, Shigematsu N, Maruki R, Urano Y, Tanaka H, Shimaya A et al. Discovery of novel forkhead box O1 inhibitors for treating type 2 diabetes: improvement of fasting glycemia in diabetic db/db mice. Mol Pharmacol 2010; 78: 961-970.
44. Gray A, Olsson H, Batty IH, Priganica L, Peter Downes C. Nonradioactive methods for the assay of phosphoinositide 3-kinases and phosphoinositide phosphatases and selective detection of signaling lipids in cell and tissue extracts. Anal Biochem 2003; 313: 234-245. (Pubitemid 36259947)
45. Bayascas JR, Wullschleger S, Sakamoto K, Garcia-Martinez JM, Clacher C, Komander D et al. Mutation of the PDK1 PH domain inhibits protein kinase B/Akt, leading to small size and insulin resistance. Mol Cell Biol 2008; 28: 3258-3272. (Pubitemid 351657090)
46. Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K et al. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther 2010; 9: 1956-1967.
47. Lindsley CW. The Akt/PKB family of protein kinases: a review of small molecule inhibitors and progress towards target validation: a 2009 update. Curr Top Med Chem 2010; 10: 458-477.
48. Denley A, Gymnopoulos M, Kang S, Mitchell C, Vogt PK. Requirement of phosphatidylinositol( 3,4,5)trisphosphate in phosphatidylinositol 3-kinase-induced oncogenic transformation. Mol Cancer Res 2009; 7: 1132-1138.
49. Kang S, Denley A, Vanhaesebroeck B, Vogt PK. Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase. Proc Natl Acad Sci USA 2006; 103: 1289-1294. (Pubitemid 43191158)
50. Jiang X, Chen S, Asara JM, Balk SP. Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits. J Biol Chem 2010; 285: 14980-14989.
51. Najafov A, Shpiro N, Alessi DR. Akt is efficiently activated by PIF-pocket- and PtdIns(3,4,5)P3-dependent mechanisms leading to resistance to PDK1 inhibitors. Biochem J 2012; 448: 285-295.
52. Shin HW, Hayashi M, Christoforidis S, Lacas-Gervais S, Hoepfner S, Wenk MR et al. An enzymatic cascade of Rab5 effectors regulates phosphoinositide turnover in the endocytic pathway. J Cell Biol 2005; 170: 607-618. (Pubitemid 41186935)
53. van den Bout I, Divecha N. PIP5K-driven PtdIns(4,5)P2 synthesis: regulation and cellular functions. J Cell Sci 2009; 122: 3837-3850.
54. van Gorp AG, Pomeranz KM, Birkenkamp KU, Hui RC, Lam EW, Coffer PJ. Chronic protein kinase B (PKB/c-Akt) activation leads to apoptosis induced by oxidative stress-mediated Foxo3a transcriptional up-regulation. Cancer Res 2006; 66: 10760-10769. (Pubitemid 44876971)
55. Stocker H, Andjelkovic M, Oldham S, Laffargue M, Wymann MP, Hemmings BA et al. Living with lethal PIP3 levels: viability of flies lacking PTEN restored by a PH domain mutation in Akt/PKB. Science 2002; 295: 2088-2091. (Pubitemid 34229473)
56. Brunet A, Datta SR, Greenberg ME. Transcription-dependent and -independent control of neuronal survival by the PI3K-Akt signaling pathway. Curr Opin Neurobiol 2001; 11: 297-305. (Pubitemid 32524094)
57. Parcellier A, Tintignac LA, Zhuravleva E, Hemmings BA. PKB and the mitochondria: AKTing on apoptosis. Cell Signal 2008; 20: 21-30. (Pubitemid 350138366)
58. Nicholson KM, Anderson NG. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 2002; 14: 381-395. (Pubitemid 34214843)
59. Wang JM, Chao JR, Chen W, Kuo ML, Yen JJ, Yang-Yen HF. The antiapoptotic gene mcl-1 is up-regulated by the phosphatidylinositol 3-kinase/Akt signaling pathway through a transcription factor complex containing CREB. Mol Cell Biol 1999; 19: 6195-6206. (Pubitemid 29399324)
60. Bujor AM, Nakerakanti S, Morris E, Hant FN, Trojanowska M. Akt inhibition up-regulates MMP1 through a CCN2-dependent pathway in human dermal fibroblasts. Exp Dermatol 2010; 19: 347-354.
61. Figueroa C, Vojtek AB. Akt negatively regulates translation of the ternary complex factor Elk-1. Oncogene 2003; 22: 5554-5561. (Pubitemid 37102690)
62. Song KS, Lee TJ, Kim K, Chung KC, Yoon JH. cAMP-responding element-binding protein and c-Ets1 interact in the regulation of ATP-dependent MUC5AC gene expression. J Biol Chem 2008; 283: 26869-26878.
63. Kok K, Nock GE, Verrall EA, Mitchell MP, Hommes DW, Peppelenbosch MP et al. Regulation of p110delta PI 3-kinase gene expression. PLoS One 2009; 4: e5145.
64. Caron E, Ghosh S, Matsuoka Y, Ashton-Beaucage D, Therrien M, Lemieux S et al. A comprehensive map of the mTOR signaling network. Mol Syst Biol 2010; 6: 453.
65. Guertin DA, Guntur KV, Bell GW, Thoreen CC, Sabatini DM. Functional genomics identifies TOR-regulated genes that control growth and division. Curr Biol 2006; 16: 958-970. (Pubitemid 43728212)
66. Chandarlapaty S, Sawai A, Scaltriti M, Rodrik-Outmezguine V, Grbovic-Huezo O, Serra V et al. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 2011; 19: 58-71.